The United Kingdom and the United States have forged a important bilateral deal that will guarantee zero tariffs on British medicine products entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to boost spending on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these vital products will remain at nothing for a period of 36 months.
This deal follows earlier threats to significantly raise tariffs on branded pharmaceutical products, with increases discussed reaching double the cost.
"This arrangement between the UK bolsters the worldwide climate for innovative medicines and brings much-needed equity to transatlantic pharmaceutical trade," an announcement said.
Trade Significance
Pharmaceuticals constitute one of the UK's most significant export categories to the America, which is by far the largest destination for major UK drugmakers.
Export figures show that in the 12 months to the end of the third quarter, the UK shipped medicines totaling £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that timeframe.
"This deal secures jobs, boosts capital expenditure and facilitates the UK to become a international leader for biotech and pharma," a minister commented.
Key NHS Changes
The pact involves several specific pledges from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a goal to increase overall NHS spending on medicines from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments were more than twenty percent.
Industry Background
The deal takes place against a ongoing dispute between the drug companies and the UK government over drug pricing and regulatory access.
The disagreement were exacerbated by claims that US consumers were charged significantly more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or abandoned, while substantial investments have been pledged toward US facilities.
A senior figure stated that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
